A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE)

Inclusion Criteria13

• Patients with current or prior diagnosis of cancer
• Confirmed PE, based on computed tomographic pulmonary angiography (CTPA) imaging showing a filling defect in at least one main or proximal lobar pulmonary artery
• Classification of intermediate risk PE as defined by the institutional PERT algorithm
• Candidate for standard of care pulmonary thrombectomy
• Age greater than or equal to 18 years. The devices for mechanical thrombectomy are not suitably sized for pediatric patients.
• ECOG performance status less than or equal to 3
• Patients must have adequate organ and marrow function as defined below:
• absolute neutrophil count ≥ 1,000/mcL
• Platelets ≥ 30,000/mcL
• As these procedures can be performed without the use of iodinated contrast, there are no specific requirements for renal function
• Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization. Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \>1 year ago, had chemotherapy-induced menopause with last menses \>1 year ago, or underwent surgical sterilization.
• All lines of prior systemic therapy are permissible. Standard concurrent chemotherapy, immunotherapy, or targeted therapy are permissible.
• Ability to understand and the willingness to sign a written informed consent document.